Back in the spring of 2010, James Lieberman landed a hot biotech stock tip. Unfortunately for him, though, it allegedly came from his boss and concerned his own company--Array BioPharma.
Array BioPharma touted its latest mid-stage study of a key pain drug as an unqualified success, beating a placebo and hitting its primary endpoint when tested in patients suffering from osteoarthritis. But when investors dug down into the release and found that its experimental med did no better than a standard treatment, its shares slid more than 11%.
The avalanche of ASCO abstracts last night triggered a flurry of news reports about the most notable new data on experimental therapies to be revealed ahead of next month's big meeting in Chicago.
Later this week the cancer drug research crowd will examine a tsunami of abstracts filed ahead of the ASCO meeting in early June in the hopes of finding a few gems.
Array BioPharma ( $ARRY ) delivered some bad news this morning about one of its experimental cancer drugs. AstraZeneca--which has licensed Array's the drug, selumetinib--came up short in in a mid-stage
Array BioPharma ($ARRY) has added another high-profile pact to its roster of big-name collaborations. Genentech has stepped in with an upfront payment of $28 million and a promise of up to $685
Boulder, CO-based Array BioPharma is taking the budget axe out to take a chop down its discovery expenses. In a release the biotech said that it is laying off 70 workers--or 20 percent of its
Shares of Boulder, CO-based Array BioPharma ( NASDAQ: ARRY ) spiked 33 percent overnight after the developer announced that it had inked a $467 million oncology pact with Novartis. The deal includes a
Shares of Array BioPharma ( ARRY ) were amped up overnight by the news that Amgen had committed $60 million upfront, research support and a schedule of unspecified milestones in exchange for the
Array BioPharma (ARRY) announced late Thursday that its rheumatoid arthritis drug candidate ARRY-162 was no more effective than a placebo in a mid-stage study. The disappointing results caused the